Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes

Executive Summary

Once-in-a-decade leadership changes stack up in Europe’s big pharma companies as the region aims for quicker and more certain drug development, although following a recent fatality an expert committee is advising caution during dose-escalation in Phase I studies.

Advertisement

Related Content

Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates
French Probe Possibility Of Manslaughter In Phase I Trial Case
European Notebook: Bayer Bids For Monsanto; Biosimilar Uptake Still Sluggish; EMA Enters Drug Pricing Debate
Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme
A Faster Finish May Depend On A Better Start – EMA's PRIME Program
European Notebook: Clinical Trial Fatality; Affordable Medicines Debate; Physician Payment Disclosure
European Notebook: Pricing Mistrust Needs Open Debate; Rasi Nears EMA Return; Market Turmoil Affects IPOs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel